CURE vs RXL: Leverage, Returns & Decay

Over three months to Nov 13, 2026, against its daily multiple, compounded, CURE finished 3.3 points short and RXL 1.8 points short.

Return gap
+20.4 pts1 year to Nov 13, 2026: CURE ahead, total return
Fee gap
0.01 ptsA year: CURE 0.94%, RXL 0.95%, per filings dated Mar 3, 2026 and Sep 25, 2026
Overlap
–No book read for both funds
Net flow
−$7m / +$2mCURE / RXL, Oct 13, 2026 to Nov 12, 2026, daily basis
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
CURE and RXL · 1 year

Growth of 100

CURE +65.7%RXL +45.3%
Growth of 100 in CURE and RXL over 1 year, Nov 13, 2025 to Nov 13, 2026, with distributions reinvested. CURE ends at 165.7 (+65.7%), RXL at 145.3 (+45.3%).

CURE +65.7%, RXL +45.3%: CURE +20.4 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.

Share

Use this comparison

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

CURE and RXL flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag the order size

Cost to trade

Hypothetical. A $10,000 order in RXL costs about $7.00 one way and $14.00 in and out, at a median spread of 0.14%. The 0.14% spread is RXL’s 30-day median, from ProShares (fund page).

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in RXL for 10 years at 0.95% a year costs about $1,542 in fees and lost growth; CURE at 0.94% would cost $1,526. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

CURE · 3 months to Nov 13, 20261.7 pts short of its stated multiple
1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%1.7 pts short of its stated multipleCURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×3 implies+39.9%CURE returned+38.2%

CURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.

Data from Aug 14, 2026 to Nov 13, 2026.
RXL · 3 months to Nov 13, 20261.3 pts short of its stated multiple
1.3 pts short of its stated multipleRXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×2 implies+26.6%RXL returned+25.3%1.3 pts short of its stated multipleRXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.XLV +13.3% ×2 implies+26.6%RXL returned+25.3%

RXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

RXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.

IQ Leverage Score

How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.

RXL scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?

CURE among the 31 leveraged ETFs at 3x, over three months

1.6, the lowest in this set98.4, the highest

RXL among the 498 leveraged ETFs at 2x, over three months

0.1, the lowest in this set99.9, the highest

A percentile among the 31 leveraged ETFs at 3x, over three months. RXL is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.

Key numbers

CURE returned, 3 months
+38.2%
RXL returned, 3 months
+25.3%
CURE from its stated multiple: compounding +1.6 pts, gap to the daily multiple −3.3 pts
−1.7 pts
RXL from its stated multiple: compounding +0.5 pts, gap to the daily multiple −1.8 pts
−1.3 pts

CURE costs 0.01 points a year less; their one-year returns differ by 20.4 points; CURE is 1.8 times larger.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+65.7%+45.3%
What its daily multiple gave, 3 months41.5%27.1%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What the underlying did, 3 monthsXLV 13.3%XLV 13.3%
What it tracksHealthcareHealth Care
Expense ratio0.94%0.95%
Net assets, as of Nov 12, 2026$209m$117m
Holdings in commonnot published

The numbers behind it

Net assets: $209m on Nov 12, 2026 for Direxion Daily Healthcare Bull 3X ETF, and $118m on Nov 13, 2026 for ProShares Ultra Health Care.

Side by side

Open the table
FundDirexion Daily Healthcare Bull 3X ETF · Aims to return three times the daily move of health care (XLV)ProShares Ultra Health Care · Aims to return twice the daily move of health care (XLV)
IssuerDirexionProShares
Sets out to return+3x+2x
Underlying assetXLVXLV
Segmentsectorsector
Fund returned, 3 months+38.2%+25.3%
Underlying returned, over that window+13.3%+13.3%
What the stated multiple implies, over that window+39.9%+26.6%
Difference from stated, over that window−1.7 pts−1.3 pts
Fund returned, 1 year+65.7%+45.3%
Difference from stated, over that window−11.4 pts−6.1 pts
Underlying volatility19%19%
Difference over the days both have tradedno shared window−1.3 pts
Expense ratio0.94%0.95%
First tradedJun 15, 2011Feb 1, 2007
Net assets, CURE as of Nov 12, 2026 and RXL as of Nov 13, 2026$209m$118m

As of Nov 13, 2026. Source: ETFIQ.

The dataFull tables, method and files, one click away.

Window by window

Open the full table
1 month+25.9%+16.8%+25.8%+17.2%+0.1 pts−0.4 pts
3 months+38.2%+25.3%+39.9%+26.6%−1.7 pts−1.3 pts
6 months+104.8%+64.6%+93.6%+62.4%+11.2 pts+2.2 pts
1 year+65.7%+45.3%+77.1%+51.4%−11.4 pts−6.1 pts
3 years+117.4%+87.6%+165.6%+110.4%−48.2 pts−22.8 pts
Since launch (Not the same days: CURE Jun 2011 · RXL Feb 2007)+3,894.1%+1,797.2%not meaningfulnot meaningfulnot meaningfulnot meaningful

From Jun 2011 to Nov 2026, CURE returned more: +3,913.0% to +1,874.7%. RXL swung less: 32.5% to 47.6%. RXL fell less at its worst: −46.5% to −63.2%.

Jun 24, 2011 to Nov 12, 2026 · 803 weekly returns · each against XLV · 19 measures

Full scorecard

Open the full table
Total return+3,913.0%+1,874.7%CUREPrice change plus distributions, reinvested.
Annualized+27.0%+21.3%CURETotal return as a yearly rate.
Price return+3,482.3%+1,726.5%CUREPrice change alone, distributions left out.
Volatility47.6%32.5%RXLSpread of weekly returns, annualized. Lower is steadier.
Downside deviation32.3%22.2%RXLLike volatility, counting only weeks below the Treasury bill rate.
Max drawdown−63.2%−46.5%RXLDeepest fall from a high to the low after it.
Upside capture734.6%315.4%100.0%CUREShare of its benchmark's rise caught in the weeks it rose.
Downside capture159.3%143.4%100.0%RXL (slight)Share of its benchmark's fall taken in the weeks it fell. Lower is better.
Beta2.972.021.00RXL lowerHow far it moves for each 1% its benchmark moves.
R squared0.990.991.00Not an edgeShare of its weekly moves its benchmark explains.
Sharpe0.710.71TieReturn above Treasury bills per unit of volatility.
Sortino1.051.03TieReturn above Treasury bills per unit of downside deviation.
Treynor0.1140.1140.122TieReturn above Treasury bills per unit of beta.
Calmar0.430.46RXL (slight)Annualized return divided by the max drawdown.
BenchmarkXLVXLVXLVThe ETF each fund is measured against.
Alpha−2.5% a year−1.7% a year0.0%CURE significantYearly return beyond what its beta to the benchmark predicts.
Alpha t-stat−2.23−1.88Not an edgeHow sure the alpha is. Below 2, it could be chance.
Alpha range−4.6% to −0.3%−3.5% to +0.1%RXL's includes zeroThe 95% range for the yearly alpha.
Information ratio0.680.65CURE (slight)Return against its benchmark per unit of tracking error.
Tracking error31.8%16.7%0.0%Not an edgeHow far weekly returns stray from the benchmark, annualized.
More

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 803 weekly returns. Cash rate: the 13-week Treasury bill.

About CURE

Over the three months to Nov 13, 2026, CURE returned 38.2%, against 41.5% for three times XLV's daily moves. Read the multiple against the whole window instead and 3 times XLV's 13.3% implies +39.9%, which makes CURE look 1.7 points short. That is not the fund's objective, which is daily. Of that 1.7, daily compounding is +1.6 points, which any 3 times fund would show over the same path, and the fund itself is −3.3 points against 3 times each day's move, compounded. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XLV moved at 19% annualized over that window. The more it moves, the further the two numbers separate.

About RXL

Over the three months to Nov 13, 2026, RXL returned 25.3%, against 27.1% for twice XLV's daily moves. Read the multiple against the whole window instead and 2 times XLV's 13.3% implies +26.6%, which makes RXL look 1.3 points short. Of that 1.3, daily compounding is +0.5 points, which any 2 times fund would show over the same path, and the fund itself is −1.8 points against 2 times each day's move, compounded. RXL aims to return +2 times XLV's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.

Questions people ask

Which came closer to its daily multiple, CURE or RXL?

Over the window to Nov 13, 2026, CURE finished 1.7 points from what its multiple implies and RXL finished 1.3 points from its own, so RXL came closer. Neither number predicts the next window: it depends on how much the underlying moves about.

Are CURE and RXL levered on the same thing?

Yes. Both are levered on health care, CURE at +3 times and RXL at +2 times the daily move.

Which one decays faster, CURE or RXL?

Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and RXL’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.

Can I hold CURE or RXL for a year?

Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.

Which is cheaper, CURE or RXL?

CURE charges 0.94% a year and RXL charges 0.95%, so CURE is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, CURE against RXL, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/cure-vs-rxl

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.